27 not yet recruiting. 27 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Not yet recruiting 27 |
| Phase 2 | 4 | Not yet recruiting 4 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Pfizer | 90 | 2027-05-01 | 2026-09-16 |
| Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma CHF5993 100/6/12.5 μg pMDI HFA-152a, Seretide Evohaler - Asthma | Phase 3 | Not yet recruiting | Chiesi Farmaceutici S.p.A. | 700 | 2026-11-16 | 2026-10-05 |
| Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis Prednisone, Compound betamethasone - Sarcoidosis, Pulmonary | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 126 | 2026-11-01 | 2026-10-15 |
| A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Almirall, S.A. | 230 | 2026-11-01 | 2026-10-14 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis TLL-018 tablets, Placebo - Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 390 | 2026-08-31 | 2026-08-25 |
| "Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis" Prednisolone, Placebo - Hypersensitivity Pneumonitis | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2026-06-01 | 2025-10-07 |
| Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis ADSTEM Inj., Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | EHL Bio Co., Ltd. | 286 | 2026-06-01 | 2026-02-12 |
| Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis Crisaborole 2%, Tacrolimus 0.1% - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 3 | Not yet recruiting | Shalamar Institute of Health Sciences | 66 | 2026-06-01 | 2025-09-09 |
| A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis MG-K10 Humanized Monoclonal Antibody Injection - Atopic Dermatitis, Atopic Eczema | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 498 | 2026-05-01 | 2026-03-18 |
| Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. Autologous whole blood therapy, Desloratadine - Chronic Idiopathic Urticaria | Phase 3 | Not yet recruiting | Cairo University | 40 | 2026-04-30 | 2026-03-20 |
| A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis MG-K10 Injection (Humanized Monoclonal Antibody), Placebo for MG-K10 - Dermatitis, Atopic | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 180 | 2026-04-17 | 2026-04-20 |
| A Study of MG-K10 in Chronic Spontaneous Urticaria MG-K10 Humanized Monoclonal Antibody Injection, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 226 | 2026-04-14 | 2026-04-22 |
| Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma tezepelumab (Arm1&Arm2) - Asthma | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 636 | 2025-12-25 | 2025-12-24 |
| A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis OPA-15406, Vehicle - Atopic Dermatitis (AD) | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Co., Ltd. | 156 | 2025-10-01 | 2025-09-15 |
| A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. GR1802 injection, Placebo - Allergic Rhinitis, Seasonal | Phase 3 | Not yet recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 144 | 2025-09-25 | 2025-09-30 |
| A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis PG-011 nasal spray 0.6%(twice daily), Placebo - Seasonal Allergic Rhinitis, SAR | Phase 3 | Not yet recruiting | Prime Gene Therapeutics Co., Ltd. | 600 | 2025-09-15 | 2025-08-28 |
| A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis Stapokibatrt - Atopic Dermatitis | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 240 | 2025-09-01 | 2025-08-06 |
| A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis OPA-15406, Vehicle - Atopic Dermatitis (AD) | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Co., Ltd. | 198 | 2025-09-01 | 2025-09-22 |
| Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab Tezepelumab, Acarizax, Placebo - Severe Asthma, Allergy to House Dust Mites | Phase 3 | Not yet recruiting | University Hospital, Montpellier | 38 | 2025-07-15 | 2025-06-10 |
| A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets) Budesonide Formoterol, Placebo, Immune Modulators (Staphylococcus and Neisseria Tablets) - Bronchial Asthma | Phase 3 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 198 | 2025-06-20 | 2025-06-05 |
Showing 20 of 27. Sign in to see all of them.
Dermatitis, Atopic (13) · Asthma (6) · Chronic Urticaria (2) · Dust Mite Allergy (2) · Rhinitis, Allergic (2) · Rhinitis, Allergic, Seasonal (2) · Alveolitis, Extrinsic Allergic (1) · Community-Acquired Pneumonia (1) · Eczema (1) · Facies (1) · Pulmonary Disease, Chronic Obstructive (1) · Rhinitis (1) · Sarcoidosis, Pulmonary (1) · Stereotyping (1)
Immune System Diseases (27) · Hypersensitivity, Immediate (26) · Skin Diseases (15) · Skin and Connective Tissue Diseases (15) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Dermatitis (13) · Genetic Diseases, Inborn (13) · Skin Diseases, Eczematous (13) · Skin Diseases, Genetic (13) · Respiratory Tract Diseases (12) · Respiratory Hypersensitivity (11) · Lung Diseases (8) · Bronchial Diseases (6) · Lung Diseases, Obstructive (6)
tezepelumab (3) · desloratadine (2) · difamilast (2) · Adjuvants, Immunologic (1) · Antibodies, Monoclonal, Humanized (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Levofloxacin (1) · Prednisolone (1) · Prednisone (1) · abrocitinib (1) · dupilumab (1) · lebrikizumab (1)
Shanghai Mabgeek Biotech.Co.Ltd (3) · Keymed Biosciences Co.Ltd (2) · Otsuka Pharmaceutical Co., Ltd. (2) · Qilu Pharmaceutical Co., Ltd. (2) · Akeso (1) · Almirall, S.A. (1) · Assistance Publique - Hôpitaux de Paris (1) · Cairo University (1) · Chiesi Farmaceutici S.p.A. (1) · Copenhagen Respiratory Research (1) · Dr. Andrew Thamboo, MD (1) · EHL Bio Co., Ltd. (1) · EMS (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · Hangzhou Highlightll Pharmaceutical Co., Ltd (1)
China (9) · Japan (2) · Argentina (1) · Egypt (1) · Germany (1) · Italy (1) · Pakistan (1) · Spain (1)
Lin Ma (2) · Nobuhito Sanada (2) · Andrew Thamboo (1) · Jens-Ulrik S. Jensen, Professor, MD, phD (1) · Jorge Fernando Maspero, MD, PhD (1) · Luo Zhang, Professor (1) · Stefan Zielen, MD (1)
2025 (4)